ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
BC Cancer at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
BC Cancer takes part in 11 sessions at ESMO 2026 in Madrid. Its work examines treatment outcomes, biomarkers and quality of life across cancers. It investigates links between inherited gene changes and pancreatic cancer characteristics and outcomes.
| Organization | ESMO 2026 Attendance |
|---|---|
BC Cancer Vancouver, Canada | |
Provincial cancer care and research agency of British Columbia, part of the Provincial Health Services Authority, with a centre in Vancouver, Canada. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Analysis of metabolic comorbidities in patients with pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Clinical characteristics and outcomes of pancreatic ductal adenocarcinoma with germline pathogenic ATM variants: A retrospective analysis Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 13:00–13:05 Welcome and Introduction Genitourinary cancers Satellite Sat Oct 24 13:05–13:30 Prostate Cancer Treatment Landscape: Unmet Needs and Emerging AR‑Directed Genitourinary cancers Abstract Mon Oct 26 11:09–11:14 Poster Mon Oct 26 12:00–12:45 Metastatic colonic neuroendocrine carcinoma: Real-world outcomes in an unselected cohort including untreated patients Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers |
Find decision makers at BC Cancer
Tell us what you sell and we’ll find the people at BC Cancer most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction